Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 6/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.45 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.45 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.45 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.45 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.45 |
| ▸ | CHRNG | P07510 | 1/20 | 0.45 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.45 |
| ▸ | CHRND | Q07001 | 1/20 | 0.45 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.43 |
| ▸ | HTR6 | P50406 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1116569 | 1.00 | LTA4H (0.52) | LTA4HPOLBCHRNB4CHRNA3CHRNB2 | |
| SCHEMBL1116568 | 1.00 | LTA4H (0.52) | LTA4HPOLBCHRNB4CHRNA3CHRNB2 | |
| SCHEMBL4374404 | 0.95 | POLB (0.57) | LTA4HPOLB | |
| SCHEMBL4381640 | 0.93 | POLB (0.56) | LTA4HPOLB | |
| SCHEMBL1751545 | 0.90 | LTA4H (0.51) | LTA4HPOLBCHRNB4CHRNA3CHRNB2 | |
| SCHEMBL4654443 | 0.90 | LTA4H (0.51) | LTA4HPOLBCHRNB4CHRNA3CHRNB2 | |
| SCHEMBL4320568 | 0.88 | LTA4H (0.58) | LTA4HPOLBCHRNB2CHRNA4 | |
| SCHEMBL13808903 | 0.88 | LTA4H (0.58) | LTA4HPOLBCHRNB2CHRNA4 | |
| SCHEMBL4324109 | 0.86 | LTA4H (0.58) | LTA4HCHRNB2CHRNA4 | |
| SCHEMBL14416942 | 0.84 | PRKCI (0.51) | LTA4HCHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103582482-B | Pharmaceutically active disubstituted triazine derivatives | 利德探索中心有限公司 | 2016-10-12 | — | — | CN | disclosed |
| US-9226929-B2 | Pharmaceutically active disubstituted triazine derivatives | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-01-05 | — | — | US | disclosed |
| US-20140179662-A1 | PHARMACEUTICALLY ACTIVE DISUBSTITUTED TRIAZINE DERIVATIVES | LEAD DISCOVERY CENTER GMBH (DE) | 2014-06-26 | — | — | US | disclosed |
| US-8669266-B2 | Quinoline-carboxamide derivatives as P2Y12 antagonists | SANOFI (FR) | 2014-03-11 | — | — | US | disclosed |
| CN-103582482-A | Pharmaceutically active disubstituted triazine derivatives | LEAD DISCOVERY CENTER GMBH | 2014-02-12 | — | — | CN | disclosed |
| EP-2680852-A1 | PHARMACEUTICALLY ACTIVE DISUBSTITUTED TRIAZINE DERIVATIVES | Lead Discovery Center GmbH (DE) | 2014-01-08 | — | — | EP | disclosed |
| US-8541593-B2 | Process for making substituted 2-amino-thiazolones | AMGEN INC. (US) | 2013-09-24 | — | — | US | disclosed |
| US-8541593-B2 | Process for making substituted 2-amino-thiazolones | AMGEN INC. (US) | 2013-09-24 | — | — | US | disclosed |
| US-8536345-B2 | Process for making substituted 2-amino-thiazolones | AMGEN INC. (US) | 2013-09-17 | — | — | US | disclosed |
| WO-2012117048-A1 | PHARMACEUTICALLY ACTIVE DISUBSTITUTED TRIAZINE DERIVATIVES | LEAD DISCOVERY CENTER GMBH (DE) | 2012-09-07 | — | — | WO | disclosed |
| US-20070004679-A1 | Androgen receptor modulators and methods of treating disease using the same | ACADIA PHARMACEUTICALS INC. | 2007-01-04 | — | — | US | disclosed |
| US-20060014739-A1 | Androgen receptor modulators and method of treating disease using the same | ACADIA PHARMACEUTICALS INC. | 2006-01-19 | — | — | US | disclosed |
| US-20040176603-A1 | Substituted nitrogen-containing heterobicycles, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-09-09 | — | — | US | disclosed |
| EP-1242081-A4 | CASPASES AND APOPTOSIS | SMITHKLINE BEECHAM CORP (US) | 2004-07-21 | — | — | EP | disclosed |
| EP-1001933-A4 | CASPASES AND APOPTOSIS | SMITHKLINE BEECHAM CORP (US) | 2002-11-06 | — | — | EP | disclosed |
| EP-1242081-A1 | CASPASES AND APOPTOSIS | SmithKline Beecham Corporation (US) | 2002-09-25 | — | — | EP | disclosed |
| US-6403792-B1 | INHIBIT PRODUCTION OF CASPASE 3 AND 7 IN MAMMALS | SMITHKLINE BEECHAM CORPORATION | 2002-06-11 | — | — | US | disclosed |
| WO-2001022966-A1 | CASPASES AND APOPTOSIS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-04-05 | — | — | WO | disclosed |
| EP-1001933-A1 | CASPASES AND APOPTOSIS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-05-24 | — | — | EP | disclosed |
| WO-1999006367-A1 | CASPASES AND APOPTOSIS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014739-A1 | Androgen receptor modulators and method of treating disease using the same | NR5A1, AR, CYP17A1 | LTA4H 1646/4885POLB 1520/4885CHRNB4 3022/4885 |
| US-20070004679-A1 | Androgen receptor modulators and methods of treating disease using the same | NR5A1, AR, ESRRA | LTA4H 1572/4885POLB 1520/4885CHRNB4 2993/4885 |
| US-20140179662-A1 | PHARMACEUTICALLY ACTIVE DISUBSTITUTED TRIAZINE DERIVATIVES | PDE5A, TESK2, PAK5 | LTA4H 3928/4885POLB 2829/4885CHRNB4 3843/4885 |
| US-20040176603-A1 | Substituted nitrogen-containing heterobicycles, the preparation thereof and their use as pharmaceutical compositions | F11, F12, F2 | LTA4H 2151/4885POLB 805/4885CHRNB4 2868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.